- Home
- BIOA vs SCPH Comparison
BIOA vs SCPH Comparison
Compare BIOA & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOA
- SCPH
- Stock Information
- Founded
- BIOA 2015
- SCPH 2013
- Country
- BIOA United States
- SCPH United States
- Employees
- BIOA N/A
- SCPH 96
- Industry
- BIOA Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- BIOA Health Care
- SCPH Health Care
- Exchange
- BIOA Nasdaq
- SCPH Nasdaq
- Market Cap
- BIOA 155.2M
- SCPH 299.0M
- IPO Year
- BIOA 2024
- SCPH 2017
- Fundamental
- Price
- BIOA $5.09
- SCPH $5.58
- Analyst Decision
- BIOA Hold
- SCPH Buy
- Analyst Count
- BIOA 4
- SCPH 3
- Target Price
- BIOA $5.67
- SCPH $12.00
- AVG Volume (30 Days)
- BIOA 153.9K
- SCPH 2.2M
- Earning Date
- BIOA 11-06-2025
- SCPH 08-07-2025
- Dividend Yield
- BIOA N/A
- SCPH N/A
- EPS Growth
- BIOA N/A
- SCPH N/A
- EPS
- BIOA N/A
- SCPH N/A
- Revenue
- BIOA $3,863,000.00
- SCPH $49,969,000.00
- Revenue This Year
- BIOA N/A
- SCPH $108.95
- Revenue Next Year
- BIOA N/A
- SCPH $78.30
- P/E Ratio
- BIOA N/A
- SCPH N/A
- Revenue Growth
- BIOA N/A
- SCPH 107.79
- 52 Week Low
- BIOA $2.88
- SCPH $1.94
- 52 Week High
- BIOA $26.62
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- BIOA 65.85
- SCPH 63.23
- Support Level
- BIOA $4.55
- SCPH $4.33
- Resistance Level
- BIOA $4.94
- SCPH $5.62
- Average True Range (ATR)
- BIOA 0.20
- SCPH 0.13
- MACD
- BIOA 0.04
- SCPH 0.04
- Stochastic Oscillator
- BIOA 98.61
- SCPH 96.51
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.